Home › Amyloidosis › NCT05040373

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Patisiran-LNP Pregnancy Surveillance Program

Who can join

All ages · Women

Inclusion Criteria:

* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

* There are no exclusion criteria for participation in this program.

About the study

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Sponsor: Alnylam Pharmaceuticals · Participants: 10 · Started: Aug 1, 2020

Contact the study team

• Alnylam Clinical Trial Information Line · Phone: 1-877-ALNYLAM
• Alnylam Clinical Trial Information Line · Phone: 1-877-256-9526

Official record on ClinicalTrials.gov — NCT05040373

Locations in the U.S.

Conditions

• Amyloidosis
• Polyneuropathies
• Familial Amyloid Neuropathies
• Familial Amyloidosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.